作为阿尔茨海默病生物标志物的ADAM10:系统性审查
M P Oliveira Monteiro E Pereira de Almeida1, R Valle Pedroso1, M Mantellatto Grigoli1
1Department of Gerontology, Federal University of São Carlos. Rod. Washington Luis, km 235, 13565-905 São Carlos, SP, Brazil.
Revue neurologique
|July 17, 2023
概括
在阿尔茨海默氏病 (AD) 患者的血液和脑脊液中,A 分解素和金属蛋白酶10 (ADAM10) 水平发生变化. 改变的ADAM10可以作为AD诊断的补充生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 遗传学 是一个遗传学.
背景情况:
- 粉素和金属蛋白酶10 (ADAM10) 对于粉素前体蛋白 (APP) 的非粉素原性裂变至关重要,防止粉素β (Aβ) 形成,这是阿尔茨海默病 (AD) 的标志.
- 在脑脊液 (CSF) 和血液 (血/血清) 中研究ADAM10为AD的诊断生物标志物提供了潜力.
结论:
- 在患有阿尔茨海默氏症的个体中,ADAM10水平在各种生物样本 (血小板,血,血清,脑液) 中明显变化.
- 这些变化存在于所有疾病阶段,将ADAM10定位为潜在的补充生物标志物.
- 需要进一步的研究来确定ADAM10的最终切断值,以准确地将AD患者与认知健康个体区分开来.
相关概念视频
01:26Alzheimer's Disease: Overview
525
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
525
01:22Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219